Is Cabaletta Bio Inc (CABA) overvalued? · $143.9M cap
Cabaletta Bio Inc (CABA) is a biotechnology company listed on US.
This page asks whether Cabaletta Bio Inc (CABA) looks expensive on cached numbers — not a short thesis.
No cached income statement for CABA, so there is no earnings base to call rich or cheap.
CABA currently screens at market cap $143.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CABA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CABA stock page for the full model, not this heading.
Not investment advice.